Bio


Dr. Payal Mapara is a licensed clinical psychologist at Stanford Health Care. She is also a clinical associate professor in the Department of Anesthesiology, Perioperative and Pain Medicine, Division of Pain Medicine at Stanford University School of Medicine.

Dr. Mapara specializes in the psychological management of chronic pain, along with cognitive behavioral therapy for mood and anxiety disorders. Her areas of expertise also include stress management, coping with chronic health conditions, and substance use disorders.

She uses evidence-based approaches, including cognitive behavioral therapy, mindfulness-based interventions, and motivational interviewing, to help patients restore function, manage symptoms, and improve their quality of life. Her approach is grounded in a whole-person health perspective that sees each person beyond their diagnosis. Her goal is to help her patients build the tools to live a life aligned with their personal values.

Dr. Mapara's research interests center on advancing behavioral approaches to chronic pain management. She focuses on improving outcomes through integrated, collaborative models of care. Her scholarly work includes a book chapter on cognitive behavioral and acceptance-based approaches to pain in primary care. She has also presented on chronic pain and opioid safety at national conferences.

Clinical Focus


  • Clinical Psychology

Academic Appointments


  • Clinical Associate Professor, Anesthesiology, Perioperative and Pain Medicine

Professional Education


  • Fellowship: San Francisco VA Medical Center Post Doctoral Psychology Fellowship (2014) CA
  • Fellowship, San Francisco VA Medical Center, Primary Care Psychology (2014)
  • Internship: Manhattan VAMC Psychology Internship Program (2013) NY
  • Internship, Margaret Cochran Corbin VA Campus, VA New York Harbor Healthcare System, Clinical Psychology (2013)
  • PhD Training: Yeshiva University Ferkauf Graduate School of Psychology (2013) NY
  • PsyD, Yeshiva University, Clinical Psychology (2013)
  • MA, Columbia University, Psychology and Education (2007)
  • BA, University of California Los Angeles, Psychology and Economics (2004)

All Publications


  • Care Models to Improve Pain and Reduce Opioids Among Patients Prescribed Long-Term Opioid Therapy: The VOICE Randomized Clinical Trial. JAMA internal medicine Krebs, E. E., Becker, W. C., Nelson, D. B., DeRonne, B. M., Jensen, A. C., Kats, A. M., Morasco, B. J., Frank, J. W., Makris, U. E., Allen, K. D., Naylor, J. C., Mixon, A. S., Bohnert, A., Reznik, T. E., Painter, J. T., Hudson, T. J., Hagedorn, H. J., Manuel, J. K., Borsari, B., Purcell, N., Hammett, P., Amundson, E. C., Kerns, R. D., Barbosa, M. R., Garvey, C., Jones, E. J., Noh, M. Y., Okere, J. B., Bhushan, S., Pinsonnault, J., Williams, B. E., Herbst, E., Lagisetty, P., Librodo, S., Mapara, P. S., Son, E., Tat, C., Marraffa, R. A., Seys, R. L., Baxley, C., Seal, K. H. 2025; 185 (2): 208-220

    Abstract

    Patients prescribed long-term opioid therapy for chronic pain often experience unrelieved pain, poor quality of life, and serious adverse events.To compare the effects of integrated pain team (IPT) vs pharmacist collaborative management (PCM) on pain and opioid dosage.This study was a pragmatic multisite 12-month randomized comparative effectiveness trial with masked outcome assessment. Patients were recruited from October 2017 to March 2021; follow-up was completed June 2022. The study sites were Veterans Affairs primary care clinics. Eligible patients had moderate to severe chronic pain despite long-term opioid therapy (≥20 mg/d for at least 3 months).IPT involved interdisciplinary pain care planning, visits throughout 12 months with medical and mental health clinicians, and emphasis on nondrug therapies and motivational interviewing. PCM was a collaborative care intervention involving visits throughout 12 months with a clinical pharmacist care manager who conducted structured monitoring and medication optimization. Both interventions provided individualized pain care and opioid tapering recommendations to patients.The primary outcome was pain response (≥30% decrease in Brief Pain Inventory total score) at 12 months. The main secondary outcome was 50% or greater reduction in opioid daily dosage at 12 months.A total of 820 patients were randomized to IPT (n = 411) or PCM (n = 409). Participants' mean (SD) age was 62.2 (10.6) years, and 709 (86.5%) were male. A pain response was achieved in 58/350 patients in the IPT group (16.4%) vs 54/362 patients in the PCM group (14.9%) (odds ratio, 1.11 [95% CI, 0.74-1.67]; P = .61). A 50% opioid dose reduction was achieved in 102/403 patients in the IPT group (25.3%) vs 98/399 patients in the PCM group (24.6%) (odds ratio, 1.03 [95% CI, 0.75-1.42]; P = .85). Over 12 months, the mean (SD) Brief Pain Inventory total score improved from 6.7 (1.5) points to 6.1 (1.8) points (P < .001) in IPT and from 6.6 (1.6) points to 6.0 (1.9) points (P < .001) in PCM (between-group P = .82). Over 12 months, mean (SD) opioid daily dosage decreased from 80.8 (74.2) mg/d to 54.2 (65.0) mg/d in IPT (P < .001) and from 74.5 (56.9) mg/d to 52.8 (51.9) mg/d (P < .001) in PCM (between-group P = .22).Outcomes in this randomized clinical trial did not differ between groups; both had small improvements in pain and substantial reductions in opioid dosage.ClinicalTrials.gov Identifier: NCT03026790.

    View details for DOI 10.1001/jamainternmed.2024.6683

    View details for PubMedID 39652356

    View details for PubMedCentralID PMC11791716